Elevance Health (ELV) stock is one of the worst S&P 500 stocks in Thursday's session. The selloff comes after the health insurance company missed bottom-line expectations for its third quarter and lowered its full-year profit forecast, citing Medicaid uncertainties.
In the three months ended September 30, Elevance Health saw revenue increase 5.2% year-over-year to $44.7 billion. However, its earnings per share (EPS) decreased 6.9% from the year-ago period to $8.37 due to increased costs in its Medicaid business.
The results were mixed compared to analysts' expectations. Wall Street was anticipating revenue of $43.4 billion and earnings of $9.66 per share, according to Yahoo Finance.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
"We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business," said Elevance Health CEO Gail Boudreaux in a statement. "We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger."
Due to its third-quarter results and "the timing mismatch between Medicaid rates and acuity," Elevance Health revised its full-year profit forecast. The company now anticipates earnings of approximately $33 per share, down from its previous guidance for earnings of $37.20.
Is Elevance Health stock a buy, sell or hold?
Elevance Health has underperformed the broader market in 2024, down nearly 7% for the year to date. Still, Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for ELV stock is $603.65, representing implied upside of almost 40% to current levels. Additionally, the consensus recommendation is a Buy.
Financial services firm Baird is one of those with an Outperform rating (equivalent to a Buy) on the large-cap stock and a $625 price target.
"We believe the power of Elevance's idiosyncratic long-term growth drivers has been significantly underappreciated by investors," wrote Baird analyst Michael Ha in an October 15 note.
Ha believes ELV is "well positioned to see immediate multiple expansion above historical levels" thanks to "numerous recent positive developments within its Carelon segment (both Service and Rx segments) and the high visibility and strength of its 2024 EPS bridge." This puts the company "fully on its way to closing the valuation multiple gap to both UnitedHealth (UNH) and Humana (HUM)," he adds.
Related Content
-
Now Is Better Than Ever for Reshopping Car Insurance, According to New StudyThe latest J.D. Power study shows that car insurance is a buyer’s market right now, as providers focus on retaining customers.
-
Stock Market Today: Wall Street Is Standing ByThe waiting is the hardest part with trade war truce talks underway and inflation data on the way.
-
Stock Market Today: Wall Street Is Standing By
The waiting is the hardest part with trade war truce talks underway and inflation data on the way.
-
The Best Covered-Call ETFs to BuyCovered-call ETFs can provide consistent, above-average income generation, but they can also cap potential upside. Here's what to look for.
-
Wealth Advisers: In Estate Planning, the End Is Just the BeginningWe need to keep the lines of communication with our clients open so that we can anticipate and help them navigate issues that arise over time.
-
Stood Up by a Radio Show: But Was It a Breach of Contract?A conscientious financial planner reschedules his clients after being invited onto a talk show and ends up losing one of them at a cost of $5,000. What does the radio show owe him, if anything?
-
Stock Market Today: Stocks Stable as Inflation, Tariff Fears EbbConstructive trade war talks and improving consumer expectations are a healthy combination for financial markets.
-
Eight Estate Planning Steps to Protect Your Loved Ones (and Your Legacy)Two-thirds of Americans don't have an estate plan. If you're one of them, these are the essential steps to take now to prevent problems for your family later.
-
The Six Pros This Adviser Says You Need to Sell Your BusinessSelling your business isn't as simple as getting the best price and walking away. These are the six professionals you'll need to get a deal across the finish line.
-
The Three C's to Financial Success: A Financial Planner's Guide to Build WealthConsistency, commitment and confidence in your chosen strategy are more critical to your financial success than finding the 'perfect' financial plan.
